Global biopharmaceutical company AstraZeneca (LSE/STO/NASDAQ:AZN) announced on Friday that it has received European Union approval for Imfinzi (durvalumab) as the first and only perioperative immunotherapy for adult patients with resectable muscle-invasive bladder cancer (MIBC).
The treatment combines Imfinzi with gemcitabine and cisplatin before surgery, followed by Imfinzi monotherapy after radical cystectomy.
The approval is based on results from the NIAGARA Phase III trial, which demonstrated a 32% reduction in the risk of disease progression, recurrence, or death compared to standard neoadjuvant chemotherapy alone. Overall survival data also showed a 25% reduction in the risk of death, with 82.2% of patients on the Imfinzi regimen alive at two years versus 75.2% in the comparator arm.
Imfinzi was well tolerated in both neoadjuvant and adjuvant settings, with no new safety signals observed. The European Society for Medical Oncology awarded the regimen its highest possible clinical benefit rating in curative settings.
Bladder cancer is the ninth most common cancer worldwide, and approximately half of MIBC patients experience recurrence after surgery. The NIAGARA trial, the largest of its kind in this setting, involved over 1,000 patients across 22 countries.
Imfinzi is already approved in the United States and several other countries for this indication, with additional regulatory reviews ongoing globally.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval